Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer Inc
Woman Max 99 years
Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US
Update Il y a 5 ans
AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER
Phase 1B: To assess the tolerability of PF-04691502 combined with letrozole in postmenopausal patients with ER positive, HER 2 negative advanced breast cancer. Phase 2: To compare the change in Ki-67...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Pfizer Global Pharamceuticals, EuCAn, Pfizer Inc
Update Il y a 5 ans
A prospective multicenter, parallel group study with a single blind phase and a double blind randomised phase, to evaluate the efficacy and satisfaction of Viagra® (Sildenafil Citrate) high dose (100mg) titration compared with 50mg dose, in men with erectile dysfunction
The primary objective of the study is to compare the efficacy of Viagra® dose titration of 50mg→100mg versus 50mg fixed dose, in men with erectile dysfunction, based on the change in subject response ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 5 ans
Immunogenicity and safety study of 1 and 2 doses of meningococcal vaccine MenACWY-TT in toddlers, persistence up to 5 years after vaccination and co-administration with pneumococcal vaccine Prevenar 13™ Hodnocení imunogenity a bezpečnosti 1 dávky a 2 dávek meningokokové vakcíny MenACWY-TT (PF-06866681) u batolat, přetrvávání protilátek až po dobu 5 let od očkování při souběžném očkování pneumokokovou vakcínou Prevenar 13®
- To evaluate the immunogenicity of MenACWY-TT after administration of 1 dose in groups ACWY1d and ACWY2d or 2 doses in group ACWY2d with respect to Serum Bactericidal Assay using rabbit complement (r...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
A Phase 2B, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Staphylococcus Aureus 4-Antigen Vaccine (SA4Ag) in Adults Undergoing Elective Posterior Instrumented Lumbar Spinal Fusion Procedures
Primary Efficacy Objective To assess the efficacy of SA4Ag in the prevention of postoperative S. aureus BSI and/or deep incisional or organ/space SSI occurring within 90 days of elective posterior ins...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12-WEEK ADMINISTRATION OF PF-00734200 TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON METFORMIN TREATMENT
To evaluate the effect of two oral doses of PF-00734200 on change from baseline to 12 weeks in HbA1c levels in subjects with T2DM on metformin.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S DISEASE PATIENTS
1. To evaluate safety, tolerability and pharmacokinetics of multiple doses of PF-04360365 administered monthly (approximately every 30 days; Cohort M) or every 3 months (approximately every 90 days; ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc,East 42nd street,New york, NY10017, USA
Update Il y a 5 ans
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTI-CENTER, COMPARATIVE, FLEXIBLE DOSE TRIAL OF PREGABALIN VERSUS GABAPENTIN AS ADJUNCTIVE THERAPY IN SUBJECTS WITH PARTIAL SEIZURES
To compare the efficacy of pregabalin (300-600 mg/day flexible dose) and gabapentin (1200-1800 mg/day flexible dose), both administered three times daily (TID), as adjunctive therapy in subjects with ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Parmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA
Update Il y a 5 ans
A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections
To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections (cIAI, c...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 5 ans
PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES
To evaluate the safety and efficacy of the 10 mg intravenous (IV) dose of tanezumab in cancer patients with pain due to bone metastases who participated in the double-blind Study A4091003 and who wish...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 5 ans
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDER
• To assess the efficacy of PD 0332334 in the treatment of GAD as measured by the change from Baseline in the HAM-A total score at Week 8. • To assess the safety and tolerability of PD 0332334 in su...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
15
16
17
18
19
20
21
22
23
24
Next